DOI: http://dx.doi.org/10.18203/2349-2902.isj20191253

Predicting outcome of neuroblastoma using N-myc status and Trk-A expression

Sankkara Barathi Chandrasekaran, Gopinath Vinayagamoorthy

Abstract


Background: Neuroblastoma is an embryonal cancer of the postganglionic sympathetic nervous system. It is the third most common pediatric cancer. The aim of the present study was to determine MYCN amplification and Trk-A expression in tissue samples of neuroblastoma cases and to correlate them with clinical status, stage and histopathology of the disease.

Methods: This prospective study was conducted at the Institute of Child Health and hospital for children [ICH & HC], Egmore during the period from June 2011 to March 2012. Ten children of age between 8 months to 12 years diagnosed with neuroblastoma were included in the study. Tissue samples were collected from all patients and sent to evaluate histopathology to confirm the presence of neuroblastoma. Gene expression was studied using TaqMan quantitative RT-PCR. Immunohistochemistry of tissues samples were done to evaluate N-myc amplification and Trk A expression.

Results: The most common presenting symptom was mass in the abdomen (60%) in the patients. In majority, stage 3 neuroblastoma was noticed in 5 (50%) cases. On histopathology, 2 (20%) cases were identified of ganglioneuro-blastoma, and 8 (80%) cases as neuroblastoma. N-myc was amplified in 3 cases (30%). No amplification was noted in all 3 cases (0%) of stage 1. None of the case in this study group showed Trk-A expression.

Conclusions: N-myc amplification was well correlated with the stages of neuroblastoma. It should be considered to be as an important prognostic marker to select appropriate treatment in children with neuroblastomas.


Keywords


Neuroblastoma, Children, N-myc amplification, Trk-A expression

Full Text:

PDF

References


De Cremoux P, Thioux M, Peter M, Vielh P, Michon J, Delattre O, et al. Polymerase chain reaction compared with dot blotting for the determination of N-myc gene amplification in neuroblastoma. Int J Cancer. 1997;72:518–21.

Stiller CA, Parkin DM. International Variations in the incidence of neuroblastoma. Internl J Cancer. 1992;52(4):538-43.

Look AT, Hayes FA, Shuster JJ, Douglass EC, Castelberry RP, Bowman LC, et al. Clinical relevance of tumour cell ploidy and N-myc gene amplification in childhood neuroblastoma: a pediatric oncologic group study. J Clin Oncol. 1991;9:581–91.

Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–4.

Schleiermacher G, Peter M, Michon J, Zucker JM, Thomas G, Magdele´NAT, et al. A multiplex PCR assay for routine evaluation of deletion of the short arm of chromosome 1 in neuroblastoma. Europ J Cancer. 1995;31:535–8.

Nakawara A, Arima-Nakawara M, Scarvarda NJ, Azar CG, Canter AB, Brodeur GM. Association between high levels of expression of the TRK gene and favourable outcome in human neuroblastoma. N Engl J Med. 1993;328:847–54.

Be´Nard J, Bourhis J, De Vathaire F, Ferrandis E, Terrierlacombe MJ, Lemerle J, et al. Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis. Progr Clin Biol Res. 1994;385:111–6.

Gilbert J, Norris MD, Haber M, Kavallaris M, Marshall GM, Stewart BW. Determination of N-myc gene amplification by differential polymerase chain reaction. Mol Cell Probes. 1993;7:227–34.

Grosfeld JL. Neuroblastoma: A 1990 overview. Pediatr Surg Int. 1991;6:9-13.

Pratap A, Sinha S, Gupta DK. Detection of Amplification in Neuroblastoma Using Polymerase Chain Reaction and Its Impact on Survival. J Indian Assoc Pediatr Surg. 2002;7:166-73.